Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC - Trial NCT06346808
Access comprehensive clinical trial information for NCT06346808 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sichuan University and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sichuan University
Timeline & Enrollment
Phase 1
May 01, 2024
May 01, 2027
Primary Outcome
Incidence of Treatment-Related Adverse Events [Safety and Tolerability]
Summary
The aim of this single center, single arm and prospective study is to explore the safety and
 efficacy of Oncolytic virus Plus Anti-PD1 and Chemotherapy as Preoperative therapy for
 Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06346808
Non-Device Trial